Current Liabilities
Lease Liability Payments - Remainder of Fiscal Year
Neurocrine Biosciences Lease Liability Payments - Remainder of Fiscal Year increased by 1.9% to $59.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.4%, from $58.30M to $59.10M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher values indicate greater near-term cash outflows, impacting short-term liquidity and working capital.
Detailed definition
The total cash outflows required to satisfy operating and finance lease obligations for the remaining portion of the cur...
Peer comparison
Standard disclosure under ASC 842 lease accounting standards.
Metric ID:
lease_liability_payments_remainder_fiscal_yearHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.80M | $16.80M | $17.90M | $17.90M | $17.90M | $17.40M | $18.50M | $18.50M | $34.70M | $35.40M | $35.40M | $58.30M | $58.30M | $58.00M | $59.10M |
| QoQ Change | — | +0.0% | +6.5% | +0.0% | +0.0% | -2.8% | +6.3% | +0.0% | +87.6% | +2.0% | +0.0% | +64.7% | +0.0% | -0.5% | +1.9% |
| YoY Change | — | — | — | +6.5% | +6.5% | -2.8% | +3.4% | +3.4% | +99.4% | +91.4% | +91.4% | +68.0% | +64.7% | +63.8% | +1.4% |
Range$16.80M – $59.10M
CAGR+43.2%
Avg YoY Growth+41.4%
Median YoY Growth+35.2%
Lease Liability Payments - Remainder of Fiscal Year at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's lease liability payments - remainder of fiscal year?
- Neurocrine Biosciences (NBIX) reported lease liability payments - remainder of fiscal year of $59.10M in Q1 2026.
- How has Neurocrine Biosciences's lease liability payments - remainder of fiscal year changed year-over-year?
- Neurocrine Biosciences's lease liability payments - remainder of fiscal year increased by 1.4% year-over-year, from $58.30M to $59.10M.
- What does lease liability payments - remainder of fiscal year mean?
- The amount of lease payments due before the end of the current fiscal year.